CytRx up on trial results
- CytRx (CYTR +2.9%) is set for a modest gap up at the open in response to its report of improved overall survival (OS) in a Phase 2b trial assessing aldoxorubicin versus doxorubicin for the treatment of patients with metastatic, locally advanced or unresectable soft tissue sarcomas.
- In the 123-subject study, the risk of death in the aldoxorubicin cohort was 27% lower than the doxorubicin cohort. Median OS was 16.0 months in the aldoxorubicin group compared to 14.4 months in the doxorubicin group but the results were not statistically significant (p=0.21). In treatment-naive patients, 90% of the study group, median OS for the two cohorts was 16.0 months versus 14.0 months, also falling short of statistical significance (p=0.14).
- Note: the results were a part of a prospectively planned secondary endpoint analysis and were not powered to demonstrate statistically significant OS.
- The company will conduct a conference call this morning at 11:00 am ET to discuss the data.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com
